Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis
Authors:
- 28 August 2018
- journal article
- review article
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 13 (5) , 407-416
Abstract
We discuss recent developments in the treatment of advanced systemic mastocytosis (advSM) with inhibitors of the KIT receptor tyrosine kinase.Keywords
This publication has 72 references indexed in Scilit:
- International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosisBlood, 2013
- Mast cell leukemiaBlood, 2013
- Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic MastocytosisPLOS ONE, 2012
- A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinibEuropean Journal of Haematology, 2011
- Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosisHaematologica, 2010
- Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosisLeukemia Research, 2009
- Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of OnsetPLOS ONE, 2008
- Systemic Mastocytosis Associated with Chronic Idiopathic MyelofibrosisThe Journal of Molecular Diagnostics, 2008
- Efficient Transplantation via Antibody-Based Clearance of Hematopoietic Stem Cell NichesScience, 2007
- Sensitive Detection of KIT D816V in Patients with MastocytosisClinical Chemistry, 2006